BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20202110)

  • 1. Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA).
    Wisniewski T; Klimko N; Laverdiere M; Kiertiburanakul S; Kliasova G; Trenschel R; Kumar RN
    Mycoses; 2011 Jul; 54(4):e148-53. PubMed ID: 20202110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry.
    Egerer G; Reichert D; Pletz MW; Kaskel P; Krobot KJ; Maertens J
    Eur J Med Res; 2012 Apr; 17(1):7. PubMed ID: 22510390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
    Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
    J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].
    Lichtenstern C; Pratschke J; Schulz U; Schmoeckel M; Knitsch W; Kaskel P; Krobot KJ; Weigand MA; Winkler M
    Anaesthesist; 2010 Dec; 59(12):1083-90. PubMed ID: 21069271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
    Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
    Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C; Ubeda-Iglesias A; Loza-Vázquez A; de la Torre MV; Raurich-Puigdevall JM; Alvarez-Sánchez B; Ortiz-Leyva C; Domínguez-Roldán JM; Socías-Crespi L; Garnacho-Montero J;
    Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
    Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.
    Winkler M; Pratschke J; Schulz U; Zheng S; Zhang M; Li W; Lu M; Sgarabotto D; Sganga G; Kaskel P; Chandwani S; Ma L; Petrovic J; Shivaprakash M
    Transpl Infect Dis; 2010 Jun; 12(3):230-7. PubMed ID: 20070619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
    Herbrecht R; Maertens J; Baila L; Aoun M; Heinz W; Martino R; Schwartz S; Ullmann AJ; Meert L; Paesmans M; Marchetti O; Akan H; Ameye L; Shivaprakash M; Viscoli C
    Bone Marrow Transplant; 2010 Jul; 45(7):1227-33. PubMed ID: 20062093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.
    Morrissey CO; Slavin MA; O'Reilly MA; Daffy JR; Seymour JF; Schwarer AP; Szer J
    Mycoses; 2007; 50 Suppl 1():24-37. PubMed ID: 17394607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
    Caillot D; Thiébaut A; Herbrecht R; de Botton S; Pigneux A; Bernard F; Larché J; Monchecourt F; Alfandari S; Mahi L
    Cancer; 2007 Dec; 110(12):2740-6. PubMed ID: 17941026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.